GlassScriptPhysician profile
Tyler Hudon
NPI 1295097012
$2,396.23
in general payments reported to CMS, 2019-2025
30 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $40.76 · 2021: $102 · 2022: $234 · 2023: $554 · 2024: $446 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $422.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $333.55 | 2022-2025 | |
| Pfizer INC. | $255.64 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $195.83 | 2019-2023 | Farxiga |
| Amgen INC. | $179.36 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $120.86 | 2019-2025 | Jardiance, Emgality, Reyvow |
| Kite Pharma, INC. | $104.49 | 2025 | Yescarta |
| Merck Sharp & Dohme LLC | $74.89 | 2019-2025 | Capvaxive, Gardasil 9, Belsomra |
| Sanofi-Aventis U.S. LLC | $73.84 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $70.37 | 2023-2024 | Jornay Pm |
| Allergan, INC. | $58.71 | 2019 | |
| Boston Scientific Corporation | $51.80 | 2023 | Lithoclast |
| Takeda Pharmaceuticals U.S.A., INC. | $51.08 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $50.69 | 2019-2022 | |
| Abbott Laboratories | $43.86 | 2024-2025 | Freestyle Libre 3 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $33.04 | 2022-2023 | |
| Glaxosmithkline, LLC. | $30.73 | 2023-2025 | Shingrix, Bexsero, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.05 | 2019-2023 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $22.55 | 2019 | |
| Idorsia Pharmaceuticals US INC | $22.20 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $22.14 | 2024 | |
| Philips North America LLC | $22.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.48 | 2019 | |
| Antares Pharma, INC. | $18.31 | 2023 | Nocdurna, Xyosted, Tlando |
| Acadia Pharmaceuticals INC | $18.12 | 2025 | Daybue |
| E.R. Squibb & Sons, L.L.C. | $16.57 | 2025 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $15.49 | 2019 | |
| Lucid Diagnostics INC. | $15.06 | 2022 | |
| Corium, LLC | $12.72 | 2024 | Azstarys |
| Medtronic USA, INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Hudon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.